- Home
- SRPT vs NBIX Comparison
SRPT vs NBIX Comparison
Compare SRPT & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRPT
- NBIX
- Stock Information
- Founded
- SRPT 1980
- NBIX 1992
- Country
- SRPT United States
- NBIX United States
- Employees
- SRPT N/A
- NBIX N/A
- Industry
- SRPT Biotechnology: Pharmaceutical Preparations
- NBIX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SRPT Health Care
- NBIX Health Care
- Exchange
- SRPT Nasdaq
- NBIX Nasdaq
- Market Cap
- SRPT 12.2B
- NBIX 13.1B
- IPO Year
- SRPT 1997
- NBIX 1996
- Fundamental
- Price
- SRPT $120.39
- NBIX $134.99
- Analyst Decision
- SRPT Buy
- NBIX Buy
- Analyst Count
- SRPT 21
- NBIX 23
- Target Price
- SRPT $179.38
- NBIX $165.00
- AVG Volume (30 Days)
- SRPT 1.0M
- NBIX 884.4K
- Earning Date
- SRPT 11-06-2024
- NBIX 02-05-2025
- Dividend Yield
- SRPT N/A
- NBIX N/A
- EPS Growth
- SRPT N/A
- NBIX 97.40
- EPS
- SRPT 1.22
- NBIX 3.73
- Revenue
- SRPT $1,640,348,000.00
- NBIX $2,242,800,000.00
- Revenue This Year
- SRPT $50.40
- NBIX $27.07
- Revenue Next Year
- SRPT $71.44
- NBIX $16.60
- P/E Ratio
- SRPT $103.94
- NBIX $36.67
- Revenue Growth
- SRPT 48.45
- NBIX 25.72
- 52 Week Low
- SRPT $89.92
- NBIX $110.95
- 52 Week High
- SRPT $173.25
- NBIX $157.98
- Technical
- Relative Strength Index (RSI)
- SRPT 50.01
- NBIX 73.61
- Support Level
- SRPT $122.12
- NBIX $125.61
- Resistance Level
- SRPT $128.73
- NBIX $130.48
- Average True Range (ATR)
- SRPT 3.87
- NBIX 2.67
- MACD
- SRPT -0.15
- NBIX 0.90
- Stochastic Oscillator
- SRPT 11.14
- NBIX 95.47
About SRPT Sarepta Therapeutics Inc. (DE)
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of company's product candidates are at an early stage of development.
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.